Highlights Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
146.1 ^USD	-0.46%		-1.20%	-6.76%

Apr. 26	Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment	MT
Apr. 25	Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson Says Europe's CHMP Recommends Approval of Rybrevant Plus Chemotherapy for Lung Cancer Treatment	Apr. 26	MT
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	Apr. 24	DJ
WHO says wider alert on contaminated J&J cough syrup 'likely'	Apr. 19	RE
US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
Medical device maker Intuitive beats estimates on strong demand for surgical robots	Apr. 18	RE
Johnson & Johnson's Q1 Had 'Some Puts and Takes,' Morgan Stanley Says	Apr. 17	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
US stocks see-saw as rising Treasury yields, Middle East tensions cap gains	Apr. 16	RE
Wall Street stocks mixed on higher Treasury yields, rate expectations	Apr. 16	RE
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	Apr. 16	MT
Correction to Johnson & Johnson Earnings Article	Apr. 16	DJ
Top Midday Stories: UnitedHealth, Johnson & Johnson, Bank of America, Morgan Stanley, PNC, Bank of New York Mellon, Northern Trust and Ericsson Report Q1 Earnings; AMD Launches New Processors; Meta's Zuckerberg Wins Case Dismissal; Planet Fitness Names New CEO	Apr. 16	MT
S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow	Apr. 16	RE
Trending : Johnson & Johnson 1Q Adjust Earnings Beat Forecasts as Company Raises Dividend	Apr. 16	DJ
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Apr. 16	MT
Johnson & Johnson Narrows Full-Year Outlook as First-Quarter Sales Miss Street Views	Apr. 16	MT
Wall St set for higher open as upbeat earnings obscure Mideast jitters	Apr. 16	RE
Johnson & Johnson: EPS up to $2.20 in Q1	Apr. 16	CF
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug	Apr. 16	MT
Stock Futures Decline Pre-Bell as Traders Await More Earnings; Asia, Europe Down	Apr. 16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST